NCT00483977

Brief Summary

The primary aim is to assess if PF-00592379 is able to reduce pain in patients with osteoarthritis of the knee.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
113

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Jun 2007

Shorter than P25 for phase_2

Geographic Reach
1 country

21 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2007

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

June 6, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 8, 2007

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2007

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2007

Completed
Last Updated

April 29, 2011

Status Verified

April 1, 2011

Enrollment Period

6 months

First QC Date

June 6, 2007

Last Update Submit

April 22, 2011

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change from baseline in the pain score averaged over the last week of treatment

    2 weeks

Secondary Outcomes (4)

  • Western Ontario and McMaster University Osteoarthritis Index (WOMAC) pain score - change from baseline to end of treatment

    2 weeks

  • Patient Global Impression of Change

    2 weeks

  • Patients Global Assessment of Osteoarthritis

    2 weeks

  • Pharmacokinetic trough levels

    2 weeks

Study Arms (3)

Oxycodone

ACTIVE COMPARATOR
Drug: Oxycodone

Placebo

PLACEBO COMPARATOR
Drug: Placebo

PF-00592379

EXPERIMENTAL
Drug: PF-000592379

Interventions

Oxycodone: oral controlled release, 20 mg, twice a day for 2 weeks

Oxycodone

Placebo: oral for 2 weeks.

Placebo

PF-00592379: oral, 30 mg, once a day for 2 weeks

PF-00592379

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female of any race
  • Between the ages of 18 and 75 years
  • Knee Pain due to osteoarthritis

You may not qualify if:

  • Pregnant
  • Participation in a clinical trial for an investigational drug and/or agent within 30 days prior to baseline
  • History of malignancy, convulsions, chronic infections, arthroscopy of the worst knee within the past year

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (21)

Pfizer Investigational Site

Mobile, Alabama, 36608, United States

Location

Pfizer Investigational Site

Tucson, Arizona, 85741, United States

Location

Pfizer Investigational Site

Carmichael, California, 95608, United States

Location

Pfizer Investigational Site

Fair Oaks, California, 95628, United States

Location

Pfizer Investigational Site

Orangevale, California, 95662, United States

Location

Pfizer Investigational Site

Roseville, California, 95661, United States

Location

Pfizer Investigational Site

Sacramento, California, 95825, United States

Location

Pfizer Investigational Site

Boca Raton, Florida, 33486, United States

Location

Pfizer Investigational Site

DeLand, Florida, 32720, United States

Location

Pfizer Investigational Site

Hollywood, Florida, 33021, United States

Location

Pfizer Investigational Site

Longwood, Florida, 32779, United States

Location

Pfizer Investigational Site

Miami, Florida, 33186, United States

Location

Pfizer Investigational Site

Louisville, Kentucky, 40213, United States

Location

Pfizer Investigational Site

Madisonville, Kentucky, 42431, United States

Location

Pfizer Investigational Site

St Louis, Missouri, 63141, United States

Location

Pfizer Investigational Site

Las Vegas, Nevada, 89146, United States

Location

Pfizer Investigational Site

New York, New York, 10022-1009, United States

Location

Pfizer Investigational Site

Durham, North Carolina, 27704, United States

Location

Pfizer Investigational Site

Cincinnati, Ohio, 45227, United States

Location

Pfizer Investigational Site

Cincinnati, Ohio, 45242, United States

Location

Pfizer Investigational Site

Richmond, Virginia, 23294, United States

Location

Related Links

MeSH Terms

Conditions

Osteoarthritis

Interventions

Oxycodone

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Intervention Hierarchy (Ancestors)

CodeineMorphine DerivativesMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic Compounds

Study Officials

  • Pfizer CT.gov Call Center

    Pfizer

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

June 6, 2007

First Posted

June 8, 2007

Study Start

June 1, 2007

Primary Completion

December 1, 2007

Study Completion

December 1, 2007

Last Updated

April 29, 2011

Record last verified: 2011-04

Locations